BioCryst to Present New ORLADEYO Clinical Data at ACAAI Meeting

Bitget2026/10/29 11:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioCryst will present four hereditary angioedema abstracts at the ACAAI annual scientific meeting in Phoenix, Nov. 12-16, 2026.
ORLADEYO presentations will cover reduced hospitalizations, emergency department visits and healthcare use among patients starting or switching preventive treatment.
Pediatric research will examine growth-related ORLADEYO dose adjustments in children.
Investigational injectable navenibart’s ALPHA-SOLAR interim results will address long-term safety, efficacy and quality of life in hereditary angioedema.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855684) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioCryst to Present New ORLADEYO Clinical Data at ACAAI Meeting

You may also like

Crypto prices